{"filing":{"accession_number":"0001759138-26-000038","cik":"0001759138","ticker":"CABA","company_name":"Cabaletta Bio, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"caba-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000038/caba-20260813.htm"},"events":[{"id":27509,"run_id":25079,"accession_number":"0001759138-26-000038","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Cabaletta Bio announced its financial results for the second quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes quarterly R\u0026D expenses ($44.4M vs. $37.6M YoY), G\u0026A expenses ($7.6M vs. $8.3M YoY), and cash position ($225.1M as of June 30, 2026), along with operational highlights and clinical milestones. This is a standard quarterly earnings release disclosing results of operations and financial condition under Item 2.02.","company_name":"Cabaletta Bio, Inc.","ticker":"CABA","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29085,"accession_number":"0001759138-26-000038","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cabaletta Bio announced its financial results for the second quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes quarterly R\u0026D expenses ($44.4M vs. $37.6M YoY), G\u0026A expenses ($7.6M vs. $8.3M YoY), and cash position ($225.1M as of June 30, 2026), along with operational highlights and clinical milestones. This is a standard quarterly earnings release disclosing results of operations and financial condition under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:33:43.900271+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29085,"accession_number":"0001759138-26-000038","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cabaletta Bio announced its financial results for the second quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes quarterly R\u0026D expenses ($44.4M vs. $37.6M YoY), G\u0026A expenses ($7.6M vs. $8.3M YoY), and cash position ($225.1M as of June 30, 2026), along with operational highlights and clinical milestones. This is a standard quarterly earnings release disclosing results of operations and financial condition under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:33:43.900271+00:00","company_name":"Cabaletta Bio, Inc.","ticker":"CABA","filing_date":"2026-08-13"}]}